Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Ariad Pharmaceuticals, Inc.    ARIA

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Ariad Pharmaceuticals, Inc. : ARIAD Announces Completion of Public Offering

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/29/2013 | 10:20pm CET

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the completion of its previously announced public offering of 15,307,000 shares of common stock at a public offering price of $19.60 per share. In addition, the underwriters have exercised an option to purchase an additional 1,182,893 shares at $19.60 per share to cover over-allotments. The total gross proceeds from the offering are approximately $323 million. Net proceeds to ARIAD are approximately $310 million after deducting underwriting discounts and commissions and estimated offering expenses.

J.P. Morgan Securities LLC, Cowen and Company, LLC and Jefferies & Company, Inc. acted as joint book-running managers and underwriters for the offering. BMO Capital Markets, Leerink Swann LLC, RBC Capital Markets, LLC and UBS Investment Bank acted as co-managers for the offering.

A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (the "SEC") and is effective. A final prospectus supplement relating to the offering has been filed with the SEC. Copies of the final prospectus supplement and accompanying prospectus may be obtained from the offices of J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 (Telephone number 866-803-9204), the offices of Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 (Telephone number 631-274-2806), or the offices of Jefferies & Company, Inc., Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY, 10022, or by telephone at 877-547-6340, or by email at Prospectus_Department@Jefferies.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About ARIAD

ARIAD Pharmaceuticals, Inc. is a global oncology company focused on the discovery, development and commercialization of medicines to transform the lives of cancer patients. For more information about ARIAD, visit the company's website at www.ariad.com.

ARIAD Pharmaceuticals, Inc.
For Investors
Kendra Adams, 617-503-7028
kendra.adams@ariad.com
or
For Media
Liza Heapes, 617-621-2315
Liza.heapes@ariad.com


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ARIAD PHARMACEUTICALS, INC
01/20 ARIAD PHARMACEUTICALS, INC. (NASDAQ : ARIA) Under Investigation for Investors ov..
01/20 TAKEDA PHARMACEUTICAL : Commences Cash Tender Offer for All Outstanding Shares o..
01/18 ARIAD PHARMACEUTICALS : Acquisition May Not Be in the Best Interests of ARIA Sha..
01/13 ARIAD SHAREHOLDER NOTICE : Faruqi & Faruqi, LLP Announces the Investigation of A..
01/13 Brower Piven Commences An Investigation Into The Proposed Sale Of ARIAD Pharm..
01/12 ARIAD PHARMACEUTICALS : to Present at the 35th Annual J.P. Morgan Healthcare Con..
01/12 ARIAD PHARMACEUTICALS : Takeda to acquire ARIAD Pharmaceuticals
01/11 TAKEDA PHARMACEUTICAL : to buy Ariad in $4.7 billion cash deal
01/10 ARIAD PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Terminat..
01/10 ARIAD PHARMACEUTICALS, INC. : Ariad Pharmaceuticals Cash Acquisition by Takeda P..
More news
Sector news : Bio Therapeutic Drugs
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/12 Investors in big pharma, biotech look to ride out Trump storm
01/12DJHot Stocks to Watch in the U.S. and Canada
01/10 Regeneron CEO says Amgen not putting patients first in patent dispute
01/09DJCELGENE : Anticipates Slowing Sales Growth for Main Drug Revlimid
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
01/20 Trump Era M&A Boom?
01/11 VALEANT : Forget About Acquisition. Takeda Has Bought ARIAD
01/11 BIOTECH FORUM DAILY DIGEST : Keytruda Continues To Power Merck; Revisiting Invit..
01/10 Google Is Watching You
01/10 Takeda to acquire ARIAD Pharmaceuticals (ARIA) - M&A Call Slides
Advertisement
Financials ($)
Sales 2016 196 M
EBIT 2016 -111 M
Net income 2016 -7,07 M
Debt 2016 157 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 24,3x
EV / Sales 2017 19,4x
Capitalization 4 603 M
More Financials
Chart ARIAD PHARMACEUTICALS, INC
Duration : Period :
Ariad Pharmaceuticals, Inc Technical Analysis Chart | ARIA | US04033A1007 | 4-Traders
Full-screen chart
Technical analysis trends ARIAD PHARMACEUTI...
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 9
Average target price 20,6 $
Spread / Average Target -13%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Paris Panayiotopoulos President, Chief Executive Officer & Director
Alexander John Denner Chairman
Manmeet Singh Soni Chief Financial Officer, Treasurer & Executive VP
Timothy P. Clackson Chief Scientific Officer
Nicholas Ventresca Chief Information Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ARIAD PHARMACEUTICALS,..90.51%4 603
AMGEN, INC.5.19%114 415
GILEAD SCIENCES, INC.-0.06%94 290
CELGENE CORPORATION-1.84%88 079
REGENERON PHARMACEUTIC..-1.00%38 329
ACTELION LTD4.58%24 308
More Results